Author: Wang, Charlie; Rademaker, Marius; Tate, Bruce; Baker, Christopher; Foley, Peter
Title: SARSâ€CoVâ€2 (COVIDâ€19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group Cord-id: h0twjmad Document date: 2021_3_30
ID: h0twjmad
Snippet: As the phase III COVIDâ€19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology Group make the following preliminary recommendations around COVIDâ€19 vaccination in dermatology patients on immunomodulatory and/or biologic agents. Vaccination against COVIDâ€19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents. There are currently insufficient data to recommend one
Document: As the phase III COVIDâ€19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology Group make the following preliminary recommendations around COVIDâ€19 vaccination in dermatology patients on immunomodulatory and/or biologic agents. Vaccination against COVIDâ€19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents. There are currently insufficient data to recommend one COVIDâ€19 vaccine or vaccine type (mRNA, recombinant, inactivated virus) over another. No specific additional risk in patients on immunomodulatory or biologic therapies has so far been identified. Data on vaccine efficacy in patients on immunomodulatory or biologic therapies are missing, so standard vaccination protocols are recommended until otherwise advised.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date